• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨碱性磷酸酶与透析患者的死亡率。

Bone alkaline phosphatase and mortality in dialysis patients.

机构信息

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Clin J Am Soc Nephrol. 2011 Jul;6(7):1752-9. doi: 10.2215/CJN.10091110. Epub 2011 May 19.

DOI:10.2215/CJN.10091110
PMID:21597029
Abstract

BACKGROUND AND OBJECTIVES

Serum alkaline phosphatase (AP) is associated with vascular calcification and mortality in hemodialysis patients, but AP derives from various tissues of origin. The aim of this study was to assess the effect of bone-specific AP (BAP) on morbidity and mortality in dialysis patients.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From a prospective cohort study of incident dialysis patients in The Netherlands, all patients with measured BAP at 12 months after the start of dialysis (baseline) were included in the analysis (n = 800; mean age, 59 ± 15 years; mean BAP = 18 ± 13 U/L). By Cox regression analyses, we assessed the impact of BAP levels on short-term mortality (6 months) and longer-term mortality (4-year follow-up).

RESULTS

High levels of BAP strongly affected short-term mortality. After adjustment for confounders, patients in the highest BAP tertile had a 5.7-fold increased risk of death within 6 months compared with patients in the lowest tertile. The effect applied to both cardiovascular and noncardiovascular mortality. Furthermore, high levels of BAP were associated with increased cardiovascular mortality in the longer term. In comparison with total AP, the effect sizes related to clinical outcomes were much higher for BAP.

CONCLUSIONS

High levels of BAP were strongly associated with short-term mortality in dialysis patients, pointing out the important impact of bone turnover. Longitudinal assessments of BAP may be useful for the treatment monitoring in clinical practice in dialysis patients.

摘要

背景与目的

血清碱性磷酸酶(AP)与血液透析患者的血管钙化和死亡率相关,但 AP 源于不同的组织来源。本研究旨在评估骨特异性 AP(BAP)对透析患者发病率和死亡率的影响。

设计、设置、参与者和测量:本研究从荷兰一项透析患者的前瞻性队列研究中选取,所有在透析开始后 12 个月(基线)时测量了 BAP 的患者(n=800;平均年龄 59±15 岁;平均 BAP=18±13U/L)均纳入分析。通过 Cox 回归分析,我们评估了 BAP 水平对短期死亡率(6 个月)和长期死亡率(4 年随访)的影响。

结果

BAP 水平高与短期死亡率密切相关。在校正混杂因素后,BAP 最高三分位组的患者在 6 个月内死亡的风险是最低三分位组的 5.7 倍。这种影响适用于心血管和非心血管死亡率。此外,BAP 水平高与长期心血管死亡率增加相关。与总 AP 相比,BAP 与临床结局相关的效应大小要大得多。

结论

BAP 水平高与透析患者的短期死亡率密切相关,表明骨转换的重要影响。BAP 的纵向评估可能对透析患者的临床实践中的治疗监测有用。

相似文献

1
Bone alkaline phosphatase and mortality in dialysis patients.骨碱性磷酸酶与透析患者的死亡率。
Clin J Am Soc Nephrol. 2011 Jul;6(7):1752-9. doi: 10.2215/CJN.10091110. Epub 2011 May 19.
2
Association between a self-rated health question and mortality in young and old dialysis patients: a cohort study.一项自评健康问题与年轻及老年透析患者死亡率之间的关联:队列研究。
Am J Kidney Dis. 2008 Jul;52(1):111-7. doi: 10.1053/j.ajkd.2008.04.001. Epub 2008 May 29.
3
Cardiovascular and noncardiovascular mortality among men and women starting dialysis.男性和女性开始透析后的心血管和非心血管死亡率。
Clin J Am Soc Nephrol. 2011 Jul;6(7):1722-30. doi: 10.2215/CJN.11331210.
4
Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).维持性血液透析患者透析前血清钠水平、透析液钠与死亡率:透析结局和实践模式研究(DOPPS)。
Am J Kidney Dis. 2012 Feb;59(2):238-48. doi: 10.1053/j.ajkd.2011.07.013. Epub 2011 Sep 23.
5
Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.血液透析中的慢性炎症与死亡率:不同肾脏替代疗法的影响。RISCAVID研究结果
Nephrol Dial Transplant. 2008 Jul;23(7):2337-43. doi: 10.1093/ndt/gfm951. Epub 2008 Feb 27.
6
Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease.骨保护素与患有心血管疾病的血液透析患者的死亡率
Clin Nephrol. 2013 Sep;80(3):161-7. doi: 10.5414/CN107803.
7
Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?透析患者胆固醇水平低——是死亡的原因还是混杂因素的影响?
Nephrol Dial Transplant. 2011 Oct;26(10):3325-31. doi: 10.1093/ndt/gfr008. Epub 2011 Feb 28.
8
Cognitive impairment and 7-year mortality in dialysis patients.透析患者的认知障碍与 7 年死亡率。
Am J Kidney Dis. 2010 Oct;56(4):693-703. doi: 10.1053/j.ajkd.2010.07.003. Epub 2010 Aug 25.
9
Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.矿物质代谢与心血管疾病发病率及死亡风险:腹膜透析患者与血液透析患者的比较
Nephrol Dial Transplant. 2006 Sep;21(9):2513-20. doi: 10.1093/ndt/gfl257. Epub 2006 Jun 24.
10
Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition.透析患者血清白蛋白与死亡率之间的关联部分可由炎症解释,而非营养不良。
J Ren Nutr. 2009 Mar;19(2):127-35. doi: 10.1053/j.jrn.2008.08.003.

引用本文的文献

1
Machine learning for identification of short-term all-cause and cardiovascular deaths among patients undergoing peritoneal dialysis.用于识别接受腹膜透析患者短期全因死亡和心血管死亡的机器学习
Clin Kidney J. 2024 Aug 29;17(9):sfae242. doi: 10.1093/ckj/sfae242. eCollection 2024 Sep.
2
Construction and validation of a predictive model for the risk of osteoporosis in patients with chronic kidney disease based on NHANES data.基于美国国家健康与营养检查调查(NHANES)数据构建并验证慢性肾病患者骨质疏松风险预测模型
PLoS One. 2025 Feb 6;20(2):e0316494. doi: 10.1371/journal.pone.0316494. eCollection 2025.
3
Higher Serum Alkaline Phosphatase Is a Risk Factor of Death and Fracture: A Nationwide Cohort Study of Japanese Patients on Dialysis.
血清碱性磷酸酶升高是死亡和骨折的危险因素:一项针对日本透析患者的全国性队列研究。
Kidney360. 2025 Mar 1;6(3):400-411. doi: 10.34067/KID.0000000656. Epub 2024 Nov 26.
4
Sensors in Bone: Technologies, Applications, and Future Directions.骨骼传感器:技术、应用及未来方向
Sensors (Basel). 2024 Sep 24;24(19):6172. doi: 10.3390/s24196172.
5
Serum alkaline phosphatase is a strong predictor of mortality in ESKD patients: analysis of the RISCAVID cohort.血清碱性磷酸酶是 ESKD 患者死亡率的强有力预测指标:RISCAVID 队列分析。
J Nephrol. 2024 Sep;37(7):1843-1851. doi: 10.1007/s40620-024-01956-1. Epub 2024 Jun 24.
6
Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview.慢性肾脏病合并矿物质与骨异常及血管钙化:概述
Life (Basel). 2024 Mar 21;14(3):418. doi: 10.3390/life14030418.
7
Glycoproteomic profile of human tissue-nonspecific alkaline phosphatase expressed in osteoblasts.成骨细胞中表达的人组织非特异性碱性磷酸酶的糖蛋白质组学概况。
JBMR Plus. 2024 Jan 22;8(2):ziae006. doi: 10.1093/jbmrpl/ziae006. eCollection 2024 Feb.
8
Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort.矿物质和骨生物标志物与德国慢性肾脏病(GCKD)队列不良心血管结局和死亡的关联。
Bone Res. 2023 Oct 20;11(1):52. doi: 10.1038/s41413-023-00291-8.
9
Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.非透析成年患者慢性肾脏病 - 矿物质和骨异常诊断与管理中使用的当前及新出现的标志物和工具
J Clin Med. 2023 Sep 30;12(19):6306. doi: 10.3390/jcm12196306.
10
Bone Disease in Chronic Kidney Disease and Kidney Transplant.慢性肾脏病和肾移植中的骨骼疾病
Nutrients. 2022 Dec 29;15(1):167. doi: 10.3390/nu15010167.